Integrin alpha V beta 8

Integrin alpha V beta 8

Integrin alpha V beta 8 詳細

Molecule Name
integrin alpha V/beta 8
分子の別称
Integrin alpha V beta 8,ITGAV&ITGB8
Drug Development Progress
治験薬の数3
市販薬剤の数0
研究&開発段階Phase 2 Clinical
ターゲットの別称
alphavbeta8 integrin
バックグランド
Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Integrin alpha V beta 8 製品リスト

Species
  • Cynomolgus(2)
  • Human(2)
  • Mouse(2)
  • Rat(1)
Tag
  • His Tag(4)
  • His Tag & Avi Tag(3)
Host
  • HEK293(7)
Conjugate
  • Unconjugated(4)
  • Biotin-labeled(3)
Grade
  • RUO(7)
Low Endotoxin
  • Yes(1)
  • No(6)
You Have Viewed 1-7 Of 7 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
NesvategrastSF-0166; OTT-166(OcuTerra Therapeutics)Phase 2 ClinicalOcuTerra Therapeutics Inc, Scifluor Life Sciences Inc
Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration
詳細
CRB-601CRB-601Phase 2 ClinicalCorbus Pharmaceuticals Holdings Inc, Uc San Francisco
Solid tumours
詳細
PLN-101095PLN-101095Phase 1 ClinicalPliant Therapeutics Inc
Solid tumours
詳細
Customer Reviews